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TumorigenesisSoft tissue sarcomas (STSs) are comparatively rare malignant tumors with poor prognosis. STSs predominantly
arise from mesenchymal differentiation. MicroRNA-34b/c, the transcriptional targets of tumor suppressor p53,
possesses tumor suppressing property. Hypermethylation of miR-34b/c has been associated with tumorigenesis
and the progression of various cancers. To determinewhether aberrantmiR-34b/cmethylation occurs in STSs,we
quantitatively evaluated the methylation level of miR-34b/c in 57 STS samples and 20 cases of peripheral blood
from healthy volunteers serving as normal controls by using matrix-assisted laser desorption ionization time-of-
ﬂight mass spectrometry. We found that miRNA34b/c is more frequently methylated in STSs (0.157 ± 0.028)
than in normal controls (0.098 ± 0.012, p = 0.038). Furthermore, the methylation levels of CpG_1.2.3,
CpG_4.5.6.7, and CpG_11.12.13 of miR-34b/c were signiﬁcantly higher in the STS group than in the normal
control group (p b 0.001). No signiﬁcant differences in the methylation levels within miR-34b/c were observed
between speciﬁc reciprocal translocations in STSs and nonspeciﬁc reciprocal translocations in STSs (0.146 ±
0.039 vs. 0.168 ± 0.035, p N 0.05). The methylation levels of miR-34b/c in STSs were associated with clinical
stage. The methylation levels of CpG_1.2.3, CpG_4.5.6.7, CpG_9.10, CpG_11.12.13, and CpG_14 in tumor-stage
III/IV tissues were signiﬁcantly higher than those in tumor-stage I/II tissues. Our ﬁndings indicated that DNA
hypermethylation of the miR-34b/c is a relatively common event in STSs and is signiﬁcantly correlated with
late clinical stage in patients with STSs. Hypermethylation of the miR-34b/c may be pivotal in the oncogenesis
and progression of STSs and may be a potential prognostic factor for STSs.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).coma; ASS1, argininosuccinate
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Soft tissue sarcomas (STSs) are a group of mesenchymal origin
malignant tumors characterized by highly biologic heterogeneity with
respect to clinical behavior, morphological features, phenotype, and
genetics. STSs encompass more than 50 distinct histological tumor
subtypes. STSs occur relatively rarely and accounts for approximately
1% of malignant tumors (Ilaslan et al., 2010; Panotopoulos et al., 2014).
Patients with STSs have poor prognosis because of rapid metastasis and
poor response to treatment. Although therapy has improved over the
years, mortality remains fairly high. Traditionally, STSs are mainly classi-
ﬁed into two categories according to the characteristics of the tumor ge-
netics. One type is speciﬁc reciprocal translocations in STSs (SRTSs) and is
characterized by simple karyotypes, which are chromosomal speciﬁc
translocations and fusion gene formation, such as synovial sarcoma
(SS), Ewing's sarcoma/peripheral primitive neuroectodermal tumor
(ES/pPNET), dermatoﬁbrosarcoma protuberan (DFSP), alveolar soft part
sarcoma (ASPS) andmyxoid liposarcoma (ML). The other type is nonspe-
ciﬁc reciprocal translocations in STSs (NRTSs) and is characterized bythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rearrangements, loss of heterozygosity and copy number alteration of
DNA, such as pleomorphic rhabdomyosarcoma (PRMS), leiomyosarcoma
(LMS), pleomorphic liposarcoma (PL), undifferentiated pleomorphic
sarcoma (UPS) and myxoﬁbrosarcoma (FS) (Mertens et al., 2010).
Previous studies have identiﬁed that genomic alterations, including
the ampliﬁcation or point mutation of oncogenes and the methylation
or deletion of tumor suppressor genes (e.g., MDM2 ampliﬁcation, P53
mutation, and PTEN methylation), are involved in the carcinogenesis
of subtype-speciﬁc STSs (Barretina et al., 2010; Hettmer et al., 2014;
Ware et al., 2014; Yin et al., 2013). Moreover, p53 mutations were
detected in 25.6% of STSs, the date has suggested that p53 mutations
may be involved in the oncogenesis of STS (Yin et al., 2012). By contrast,
epigenetic alterations such as DNA methylation is an alternative
mechanism of gene inactivation that occurs in the process of tumor
progression and thus changes gene expression level without altering
the DNA sequence (Liu et al., 2013; Zhu et al., 2012). Similar to genetic
mutations, transcriptional silencing owing to gene promoter CpG unit
methylation is stably inherited by the next cell generation and may
therefore enable the clonal expansion of a cell populationwith a selective
advantage during tumor progression. Existing studies have shown that
various tumor suppressor genes are frequently methylated in STSs and
contribute to tumorigenesis. For example, epigenetic silencing of tumor
suppressor gene BMP2 via CpG hypermethylation fosters tumor growth
and progression in rhabdomyosarcoma, and the suppression of BMP2
by epigenetic silencingmay be critical in the genesis of rhabdomyosarco-
ma (Wolf et al., 2014). Thehypermethylation of a novel tumor suppressor
geneASS1 promoterwas detected andwas strongly associatedwithASS1
protein deﬁciency within myxoﬁbrosarcoma, which was linked to
increased tumor stage and grade, and independently predicted worse
survival (Huang et al., 2013). Fromwhat has been discussed above, iden-
tifying the molecular markers and pathogenesis of STSs, especially the
detection of abnormal methylation, may be useful for the diagnosis and
therapeutic regimens of STSs.
MicroRNAs (miRNAs) are a highly conserved class of small
non-coding single-stranded RNAs that transcriptionally or post-
transcriptionally regulate the level of gene expression through
speciﬁc binding at regulatory regions in multicellular organisms.
MiRNAs are involved in many basic biological and physiological regula-
tory processes, including cell differentiation, proliferation, apoptosis,
stress response, and inﬂammation (Anwar and Lehmann, 2014;
Kishore et al., 2014). Epigenetic inactivation is one of the factors that
inﬂuenced the regulatory mechanism of microRNAs. The transcription
of miRNA as a protein-encoding genemight be inactivated by promoter
hypermethylation. Widespread miRNA is dysregulated in STSs by
changes in epigenetic silencing or protein expression, thus resulting in
cellular malignant transformation (Diao et al., 2014; Karnuth et al.,
2014). Among the variousmiRNAs, themiR-34b/c gene, which localizes
to chromosome 11q23.1 and belongs to the miR-34 family, shares a
common primary transcript and acts as a potential tumor suppressor
that is directly regulated by p53 (Corney et al., 2007; Wong et al.,
2011; Zhang et al., 2014). MiR-34b/c is involved in mediated cellular
responses, such as cell cycle arrest (Yan et al., 2014), apoptosis, and
metabolic regulation (Zhang et al., 2014). The reduced or deleted
expression of miR-34b/c might contribute to diverse human cancers
because of the aberrant CpG island methylation of its promoter
(Beresneva et al., 2013; Nadal et al., 2013; Ng et al., 2014; Wu et al.,
2014; Xie et al., 2014). However, only one study has reported themeth-
ylation ofmiR-34b/c gene promoters in STS cell lines and tissue samples
(Vogt et al., 2011), but themethylation level of themiR-34b/c individual
CpG unit and the exact function of DNA hypermethylation of miR-34b/c
in STSs remains unclear.
In the present study, we accordingly therefore hypothesized wheth-
er miR-34 b/c CpG island aberrant methylation preferentially occurs in
STSs and correlateswith clinical parameters. To address these problems,
we quantitatively evaluated the methylation level of the miR-34b/cindividual CpG unit by usingmatrix-assisted laser desorption ionization
time-of-ﬂight mass spectrometry (MALDI-TOF MS) with 57 STS sub-
jects, and then assessed the association between the methylation status
of every CpG unit within the miR-34b/c and the clinicopathologic
features of the patients with STSs. Results indicated that DNA hyperme-
thylation of the miR-34b/c is a relatively common event in STSs and is
signiﬁcantly correlated with late clinical stage in patients with STSs.
Hypermethylation of the miR-34b/c may be pivotal in the oncogenesis
and progression of STSs and may be a potential prognostic factor for
STSs.
2. Materials and methods
2.1. Ethics statement
Written informed consent was obtained from all participating
patients in the study. This study was approved by the Research Ethics
Committee at the First Afﬁliated Hospital of Shihezi University School
of Medicine, PR China. The experiment was conducted in accordance
with the ethical guidelines of the Declaration of Helsinki. All specimens
were handled and made anonymous according to the ethical and legal
standards.
2.2. Sarcoma tissue samples
We analyzed a total of 57 eligible FFPE tissue samples from a collec-
tion of STS patients registered in the Department of Pathology, The First
Afﬁliated Hospital of Shihezi University School of Medicine, China,
during 1976 to 2010. No restrictions regarding sex, age and disease
stage were set. We excluded such patients who had undergone surgery
(except diagnostic biopsy), chemotherapy, radiotherapy or any blood
transfusion in thepreceding sixmonths before recruitment. Thediagno-
ses of all original slides, including hematoxylin–eosin (HE) and immu-
nohistochemistry staining from each case, were conﬁrmed by two
experienced pathologists. Each parafﬁn block was reviewed to assure
that at least 70% of the tumor cells were present before sectioning and
DNA extraction. Patients with STS subtypes were composed of 28
cases of SRTSs (5 cases of SS, 11 cases of ES/pPNET, 8 cases of DFSP, 1
case of ASPS, and 3 cases of ML) and 29 cases of NRTSs (1 case of
PRMS, 5 cases of LMS, 1 case of PL, 18 cases of UPS, and 4 cases of FS).
A total of 20 cases of peripheral blood collected in ethylenediaminetet-
raacetic acid (EDTA) were obtained from healthy volunteers serving as
normal controls. In this study, various clinic-pathological characteristics
of patients with STSs were investigated as follows. There were 35
(64.1%) males and 22 (38.6%) females in the case group. The age was
45.74 ± 6.69 (mean ± SD) years for the STS samples. The samples
included 14 (24.6%) well-differentiated patients (G1), 14 (24.6%) mod-
erately differentiated patients (G2), and 29 (50.8%) poorly differentiat-
ed patients (G3). 30 (65.2%) were classiﬁed as stage I/II and 16 (34.8%)
as stage III/IV.
2.3. Isolation of genomic DNA
Total genomic DNA was extracted from the 57 FFPE STS tissues by
means of proteinase K lysis and subsequent phenol–chloroform extrac-
tion. Twenty sections (5 μmeach) from each FFPE tissue specimenwere
shredded with 1.5 ml of xylene in a 2 ml centrifugation tube placed up-
side down. The sections were applied to mix up the samples for 5 min,
followed bymixing at 10min in a 55 °Cwater-bath. After centrifugation
(5 min at 10,000 rpm), supernatants were removed. The cell pellets
were washed with 1.5 ml of absolute ethanol and air-dried for evapora-
tion of residual ethanol. The sampleswere lysed overnight at 60 °C with
250 μl of lysis buffer (50 mM Tris pH 8.4, 1 mM ethylenediaminetetra-
acetic acid (EDTA), 0.5% [v/v] Tween 20) and 50 μl of proteinase K
(20 mg/ml) in a thermomixer. Proteinase K was inactivated (5 min,
95 °C). High molecular weight DNA extraction was performed by
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2013). After elution in 30 μl of elution buffer, genomic DNAwas isolated
from 20 healthy human peripheral blood used as normal controls by
using standard phenol–chloroform extraction methods as previously
described (Di Pietro et al., 2011). DNA concentrations were measured
using a NanoDrop Instrument (Thermo Scientiﬁc, Wilmington, DE,
USA). As internal control, all puriﬁed genomic DNA samples were suc-
cessfully tested by polymerase chain reaction with human β-globin
primers for: 5′-CAGACACCATGGTGCACCTGAC-3′ and rev: 5′-CCAATA
GGCAGAGAGAGTCAGTG-3′, indicating that the suitable quality and
quantity of DNA can be used to detect the proﬁle of miR-34b/c methyl-
ation. The eluted genomic DNA was stored at −20 °C until used as a
template for the following test.
2.4. Bisulﬁte treatment
GenomicDNAwas treatedwith sodiumbisulﬁte using anEZ-96DNA
methylation kit (Zymo Research) according to manufacturer's recom-
mendations with minor modiﬁcations. This process converts the non-
methylated cytosine residues to uracil, whereas the methylated cyto-
sine remains unchanged. Brieﬂy, we add 5 μl of M-dilution buffer to
10 μl DNA sample in a conversion plate and then adjust the total volume
to 50 μl withwater.Wemix each sample by pipetting up and down. The
mixture was incubated for 15 min at 37 °C. After the above incubation,
100 μl of the prepared CT-conversion reagentwas added to each sample
and thenmixed. This reactionmixwas repeatedly heated between 95 °C
for 30 s and 55 °C for 15min in a PCRmachine for 20 cycles followed by
the washing and elution steps.
2.5. PCR and in vitro transcription
We identiﬁed the sequence of has-miR-34b/c CpG island (CGI) with
the use of the UCSC genome browser (http://genome.ucsc.edu/)
(chr11:110888379-110889102, %GC = 58.1 and Obs/ExpCpG = 0.73,
Fig. 1). We then analyzed the CpG density and CpG sites of target
sequences of has-miR-34b/c with extreme precision for the PCR primer
design. One primer set was designed for the methylation analysis
of the has-miR-34b/c by using EpiDesigner software (http://www.
epidesigner.com). When the primers were designed, we added a T7
promoter tag (23 bp) and 8 bp insert to reverse the primer for in vivo
transcription. After which, a 10mer tag was added to the forward prim-
er to balance the PCR primer length. We used the following primer
pairs: miR-34b/c tag-forward, 5′-aggaagagagGTTATATGGATGGAGGGG
TTTTAT-3′ and T7-reverse, 5′-cagtaatacgactcactatagggagaaggctACTACC
ATCAAAACAAAACACAACA-3′. Subsequently, 2 μl of bisulﬁte-treated
DNA was ampliﬁed by PCR as previous described (Lodygin et al.,
2008). The PCR product was treated by adding 1.7 μl of nuclease freeFig. 1. Information on miR34b/c CpG islands. The red ﬁlled box coverage areawater (Sequenom) and 0.3 μl of shrimp alkaline phosphatase (SAP;
Sequenom). The reaction was incubated at 37 °C for 20 min, after
which SAP was inactivated for 5 min at 85 °C.
We used 2 μl of SAP-treated PCR mixture as a template in a total
volume 7 μl transcription reaction (all reagents from Sequenom). In
vivo transcription and T cleavage were simultaneously performed at
37 °C for 3 h, and then the product sample was puriﬁed. Further exper-
imental details have been previously described (Coolen et al., 2007).
2.6. MALDI-TOF-MS measurements
Using MassARRAY Nanodispenser robotically dispensed 22 nl of
cleavage reaction onto silicon chips preloadedwithmatrix (SpectroCHIP,
Sequenom). The DNA methylation status was quantitatively detected,
and mass spectra were recorded using MALDI-TOF MS (Sequenom, San
Diego, USA). Methylation data of individual units were generated by
the EpiTyper v1.0.5 software (Sequenom).
2.7. Statistical methods
We used hierarchied cluster analysis to compare the methylation
levels of miR-34b/c CpG units between STSs and normal control and
to identify siteswith a statistically signiﬁcant difference by using Cluster
3.0 software and TreeView software. We then used Kruskal–Wallis test
andMann–Whitney test to analyze the difference inmethylation levels.
The signiﬁcance level was set as a p value of less than 0.05. Statistical
analysis was performed using the Mann–Whitney test to compare the
methylation rate among SRTSs, NRTSs and normal control. Given that
repeated hypothesis tests caused a type-one error α to expand, we
should redeﬁne the inspection level. The correction formula was α′ =
α / N (‘N’ was the number of inspection), N = n(n − 1) / 2 (‘n’ was
the number of groups for inspection), be α′ = 2α / n(n − 1) and
α′ = 2 ∗ 0.05 / 3 ∗ (3 − 1) = 0.017. Thus, signiﬁcance was set as a p
value of less than 0.017. The statistical analyses were performed using
the Statistical Package for the Social Science (SPSS) (IBM Corp, Armonk,
NY) version 17.0.
3. Results
3.1. Frequent epigenetic silencing of miR-34b/c in STSs
We performed quantitative high-throughput analysis of DNAmeth-
ylation patterns by using the MassARRAY system within the miR-34b/c
CpG island, which contains 22 CpG sites. The methylation patterns of
the miR-34b/c CpG island were studied in all the samples collected
from STSs (n = 57) and normal controls (n = 20). A region of the
miR-34b/c that is 280 base pairs in length and contains 22 CpG sitesindicated the ampliﬁed region of miR34b/c CpG island-speciﬁc primers.
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MassARRAY system. In essence, not all spectral changes could be detect-
ed because some fragments were either too small or too large, thus
exceeding the available mass window. The length of the fragment may
also inﬂuence the result of observation. Among these CpG units, 1 CpG
unit (6 CpG sites) did not yield successful measurements. The ﬁnal
data set consisted of 7 CpG units (16 CpG sites) from 77 samples. More-
over, 82% of the CpG units yielded successful measurements and had
good results for N90% of the samples.
We conducted a hierarchical clustering of the CpG unit methylation
and the combined tumor and normal control to explore any natural
groupings in this data set (Fig. 2). Hierarchical cluster analysis of CpG
units reveals two primary clusters: one cluster contains CpG_9.10,
CpG_4.5.6.7, CpG_11.12.13, CpG_8, and CpG_14, was identiﬁed to have
a higher methylation level, whereas the other contains CpG_1.2.3 and
CpG_15.16. The corresponding CpG units tended to cluster together,
showing similar intragenicmethylation patterns. The observed patterns
in the cluster analyses show thatmethylation patterns of normal control
are notably different from those observed in STS tissues.
The results of methylation quantiﬁcation methodology indicate that
different degrees of methylation changes were detected in the target
region of miRNA34b/c gene among 57 STSs and 20 normal controls.
The overall methylation level within the target region of miRNA34b/c
was statistically higher in STSs than in normal control (0.157 ± 0.028
vs. 0.098 ± 0.012, p = 0.038) (Fig. 3A). The results demonstrate the
occurrence of aberrant methylation of miRNA34b/c in STS samples
and indicate that miRNA34b/c is abundantly methylated in STSs. The
relationship between overall methylation level of miRNA34b/c and
clinicopathologic features was further evaluated. There were signiﬁcant
association between overall methylation level of miRNA34b/c and gen-
der, tumor TNM stage. However, there were no signiﬁcant association
between overall methylation level of miRNA34b/c and age, location of
the primary tumor, tumor grade, tumor size, and tumor different histol-
ogy, as shown in Table 1.3.2. Difference in methylation level of miR-34b/c between SRTSs and NRTSs
The difference in the quantitativemethylation patterns of every CpG
unit within themiR-34b/c between the 28 SRTSs and the 29 NRTSs was
further evaluated. Overall, high degrees of methylation in miR-34b/c
genes have been observed in SRTSs compared with normal controlsFig. 2. Hierarchical cluster analysis of 7 CpG unit methylation proﬁles of miR34b/c in 77 sampl
resents a CpG unit, which can be a single CpG site or a combination of CpG sites. Each column
red bars, tumor samples. Right vertical axis, CpG units, which is a single CpG site or a combinatio
in the central image plotwith values ranging from zero (red) to one (bright yellow; see color key
Ewing's sarcoma/peripheral primitive neuroectodermal tumor; ASPS, alveolar soft part sarco
protuberan; LMS, leiomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; PRMS, pleomo(0.146± 0.039 vs. 0.098± 0.012, p=0.023). The aberrantmethylation
level of miR-34b/c was signiﬁcantly higher in NRTSs than in normal
controls (0.168±0.035 vs. 0.098±0.012, p=0.042) (Fig. 3B). However,
no statistical differences were observed in methylation patterns
between SRTSs and NRTSs in themiR-34b/c genes (p N 0.05). As regards
the CpG unit of miR-34b/c, the mean methylation levels at CpG_1.2.3,
CpG_4.5.6.7, CpG_8, CpG_9.10, CpG_11.12.13, CpG_14, and CpG_15.16
were based on the differences between SRTSs (mean methylation =
18.05%, 10.55%, 15.0%, 10.29%, 9.33%, 20.29%, 18.33%, respectively) and
NRTSs (mean methylation = 13.35%, 16.48%, 23.25%, 11.54%, 16.04%,
25.64%, 11.0%, respectively) (p N 0.05).3.3.Methylation levels at individual CpG islands along themiR-34b/c target
region
We then examined themethylation level of individual CpG islands of
the miR-34b/c target region (Fig. 3C, Table 2). For miR-34b/c, some
variability was observed in the methylation status of individual CpG
units within the sequenced region. The results showed that themethyl-
ation rate of one CpG island (CpG_9.10) was lower in the STS group
(mean methylation = 10.89%) than in the normal control group
(meanmethylation=14.95%), and themethylation rates of the remain-
ing three CpG units containing CpG_8, CpG_14, and CpG_15.16 (mean
methylation = 19.05%, 23.02%, 14.88%, respectively) were numerically
higher than those of the normal control group (mean methylation =
12.65%, 19.16%, 5.45%, respectively). Moreover, the methylation rate of
three CpG islands of miR-34b/c (CpG_1.2.3, CpG_4.5.6.7, and
CpG_11.12.13) was signiﬁcantly higher in the STS group (mean
methylation= 15.45%, 13.84%, 12.98%, respectively) than in the normal
control group (meanmethylation= 5.47%, 5.8%, 5.4%, respectively) (all
the p values are less than 0.001).
We further evaluated whether the methylation level of individual
CpG islands of miR-34b/c target region differed among the SRTS
group, NRTS group, and normal control group (Fig. 3D, Table 3). We
found heterogeneity between individual CpG units. The result showed
that apart from CpG_9.10, the methylation level of six CpG units was
numerically higher in samples of SRTSs and NRTSs than in the normal
control. In addition, the mean methylation levels at CpG_1.2.3,
CpG_4.5.6.7, and CpG_11.12.13 were signiﬁcantly higher within SRTSs
and NRTSs than in the normal control (p b 0.001). We found heteroge-
neity among individual CpG units.es derived from 57 STS samples and 20 normal control tissue samples (N). Each row rep-
represents a sample. Bottom horizontal axis, tissue samples; blue bars, normal samples;
n of CpG sites. The relativemethylation of each fragment within each sample is presented
). Gray represents technically inadequate ormissing data. SS, synovial sarcoma; ES/pPNET,
ma; ML, myxoid liposarcoma; PL, pleomorphic liposarcoma; DFSP, dermatoﬁbrosarcoma
rphic rhabdomyosarcoma; FS, myxoﬁbrosarcoma.
Fig. 3. Evaluation of DNA methylation of miRNA34b/c gene. (A) Comparison of overall methylation status of miRNA34b/c between STSs and normal control (NC) subjects. (B) Overall
methylation levels are displayed within themiRNA34b/c gene as box plots in SRTS and NRTS carrier compared with normal controls. (C) Average methylation levels of seven informative
CpG units in miRNA34b/c between STSs and normal control subjects. (D) Average methylation levels of seven informative CpG units in miRNA34b/c between SRTSs, NRTSs, and normal
control subjects. **p b 0.001. Error bars represent standard error.
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tients with STSs
The association between the patterns of the quantitative methylation
of everyCpGunitwithin themiR-34b/c and the clinicopathologic features
of the 57 patients with STSs was further evaluated (Table 4). The CpG_14
methylation levels of miR-34b/c in male tumor tissues were remarkably
greater than those in female tumor tissues (27.29% vs. 17.17%, p =
0.047; two-tailedMann–WhitneyU-test).Moreover, the CpG_14methyl-
ation levels of miR-34b/c were closely related to age, given that the
methylation levels in patients over 45 years old were signiﬁcantly higher
than those in patients under 45 years old (29.05% vs. 18.70%, p = 0.034;
two-tailed Mann–Whitney U-test). The CpG_9.10 methylation levels of
miR-34b/c in STSs had a positive correlation with pathological grade
(p = 0.039; two-tailed Kruskal–Wallis H test). The results also showed
that the CpG_1.2.3 methylation levels of miR-34b/c were correlated
with tumor size. Methylation levels were higher in tumors with
diameters larger than 5.8 cm than in those less than 5.8 cm in diameter
(p = 0.027; two-tailed Mann–Whitney U-test). The methylation levels
of miR-34b/c in STSs were associated with clinical stage. The CpG_1.2.3,
CpG_4.5.6.7, CpG_9.10, CpG_11.12.13, and CpG_14 methylation levels in
tumor-stage III/IV tissues were also signiﬁcantly higher than those in
stage I/II tissues (31.36% vs. 12.04%, p = 0.002; 29.91% vs. 8.84%, p =
0.001; 24.06% vs. 3.74%, p b 0.001; 27.50% vs. 8.17%, p = 0.005; 35.08%
vs. 18.15%, p = 0.020, respectively; two-tailed Mann–Whitney U-test,
Fig. 4). However, no correlationwas found between the CpG unitmethyl-
ation of miR-34b/c and the tumor location of STSs.4. Discussion
We present a quantitative high-throughput assay for the methyla-
tion analysis ofmiR-34b/c within STSs by using theMassARRAY system.The MassARRAY system is a tool that enables high-throughput detec-
tion and quantitative analysis of methylation at one individual CpG
site or CpG unit of a target nucleotide fragment. This tool generates pre-
cise data that represent the ratio of methylation events on individual
CpG sites by MALDI-TOF MS. Genomic DNA converts the non-
methylated cytosine (C) into uracil (U), whereas methylated cytosine
remains unchanged after bisulﬁte treatment. C/T changes are reﬂected
as G/A changes in the cleavage products generated from the reverse
strand by the base-speciﬁc cleavage reaction. These G/A changes will
yield a mass difference of 16 Da for each CpG site, as precisely detected
by the compactMassARRAY analyzer. In themass spectrum, the relative
amount of methylated DNA can be calculated by comparing the signal
intensity between the mass signals of methylated and non-methylated
templates to yield quantitative results for each cleavage product.
MiRNAs are essential post-transcriptional regulators that regulate
gene expression by binding to partially complimentary sequences of
target messenger RNAs (mRNA). The interaction leads to mRNA degra-
dation or protein synthesis repression, resulting in protein expression
downregulation of the target gene. Therefore, dysregulation of miRNAs
can inﬂuence the expression of oncogenes or tumor suppressor genes.
MiRNA34b/c, the transcriptional targets of tumor suppressor p53, has
an important function in the p53 signaling network. The expression of
miRNA34b/c is activated by p53 regulation, miR-34b/c has been
indicated to have a tumor-suppressing property. Thus, miR-34b/c was
shown to suppress tumor development by inhibiting several processes,
including cell proliferation, apoptosis, metastasis, cell cycle, adhesion-
independent colony formation, and epithelial–mesenchymal transition
(Corney et al., 2007; Rokavec et al., 2014). Epigenetic inactivation of
miR-34b/c by DNA hypermethylation was identiﬁed in a number of
different cancers and was conﬁrmed to be related to tumorigenesis
and pathogenesis.
Methylation of miR-34b/c was detected in primary lung adenocarci-
noma (46%, 64/140) and lung adenocarcinoma cell lines (40%, 6/15).
Table 1
The relationship between overall methylation level of miRNA34b/c and clinicopathologic
features for the 57 patients with STSs.
Patient characteristic Number of patients (%) Methylation level (%) p value
Gender 0.025
Male 35 (61.4) 19.58 ± 4.42
Female 22 (38.6) 10.88 ± 3.24
Age (years) 0.414
b45 29 (52.7) 14.42 ± 4.90
≥45 26 (47.3) 18.74 ± 4.70
Mean 45.74 ± 6.69
Range 11–77
Tumor location 0.919
Head and neck 6 (10.7) 18.09 ± 5.40
Limb 24 (42.9) 18.21 ± 3.68
Trunk wall 18 (32.1) 14.95 ± 1.43
Retroperitoneal 4 (7.1) 11.38 ± 5.24
Other 4 (7.1) 13.87 ± 7.91
Gradea 0.091
G1 14 (24.6) 14.52 ± 1.65
G2 14 (24.6) 10.83 ± 4.85
G3 29 (50.8) 19.64 ± 5.06
Tumor size 0.435
b5.8 cm 24 (52.2) 14.92 ± 2.91
≥5.8 cm 22 (47.8) 19.42 ± 5.10
Median 5.8 cm
TNM stage 0.000
I/II 30 (65.2) 11.18 ± 4.25
III/IVb 16 (34.8) 28.40 ± 6.51
Histology 0.122
SRTSs 28 (49.1) 14.55 ± 4.49 0.079
SS 5 (8.8) 18.18 ± 1.58
ES/pPNET 11 (19.3) 12.24 ± 6.26
DFSP 8 (14.0) 12.06 ± 2.83
ASPS 1 (1.7) 8.33
ML 3 (5.3) 26.42 ± 6.38
NRTSs 29 (50.9) 16.76 ± 5.68 0.172
PRMS 1 (1.7) 15.83
LMS 5 (8.8) 11.65 ± 1.89
PL 1 (1.7) 27.33
UPS 18 (31.7) 21.05 ± 7.58
FS 4 (7.0) 8.61 ± 3.35
Note: p-values were calculated by nonparametric test. SRTSs, speciﬁc reciprocal transloca-
tions in STSs. NRTSs, nonspeciﬁc reciprocal translocations in STSs. SS, synovial sarcoma;
ES/pPNET, Ewing's sarcoma/peripheral primitive neuroectodermal tumor; DFSP,
dermatoﬁbrosarcoma protuberan; ASPS, alveolar soft part sarcoma; ML, myxoid
liposarcoma; PRMS, pleomorphic rhabdomyosarcoma; LMS, leiomyosarcoma; PL, pleo-
morphic liposarcoma;UPS, undifferentiatedpleomorphic sarcoma; FS,myxoﬁbrosarcoma.
a Histologic grade was with reference to WHO classiﬁcation published in 2013.
b TNM stage was based on the UICC criteria published in 2009.
Table 3
Comparison of the methylation rate of miR34b/c gene CpG island among three groups.
CpG unit CpG site NC/SRTSs/NRTSs SRTSs/NRTSs
χ2 values p values Z values p values
Unit 1 CpG_1.2.3 13.006 b0.001 −0.736 0.462
Unit 2 CpG_4.5.6.7 18.258 b0.001 −1.447 0.148
Unit 3 CpG_8 3.508 0.173 −0.504 0.615
Unit 4 CpG_9.10 0.365 0.833 −0.365 0.715
Unit 5 CpG_11.12.13 17.875 b0.001 −1.871 0.061
Unit 6 CpG_14 0.794 0.672 −0.661 0.509
Unit 7 CpG_15.16 4.638 0.098 −1.360 0.174
Note: bold face representing signiﬁcant data.
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primary tumors and cell lines, especially those with P53 mutations.
MiR-34b/c methylation has independent prognostic value in patients
with early-stage lung adenocarcinoma. The re-expression of miR-34b/
c results in a less aggressive phenotype in lung adenocarcinoma cell
lines (Nadal et al., 2013). Wu et al. showed that miR-34b/c methylation
has been found in 80 of 82 (97.5%) colorectal cancer tissue samples,
which suggests that the abnormal methylation of miR-34b/c genes
might be regarded as a potential biomarker for the noninvasive screen-
ing and diagnosis of colorectal cancer (Wu et al., 2014). In addition,Table 2
Themeanmethylation level of miR34b/c gene CpG islandwithin STSs and normal tissues.
CpG unit CpG Site Normal control tissue STSs p values
Unit 1 CpG_1.2.3 0.0547 ± 0.0023 0.1545 ± 0.0324 b0.001
Unit 2 CpG_4.5.6.7 0.0580 ± 0.0032 0.1384 ± 0.0205 b0.001
Unit 3 CpG_8 0.1265 ± 0.0084 0.1905 ± 0.0207 0.067
Unit 4 CpG_9.10 0.1495 ± 0.0427 0.1089 ± 0.0206 0.705
Unit 5 CpG_11.12.13 0.0540 ± 0.0029 0.1298 ± 0.0204 b0.001
Unit 6 CpG_14 0.1916 ± 0.0182 0.2302 ± 0.0218 0.481
Unit 7 CpG_15.16 0.0545 ± 0.0058 0.1488 ± 0.0587 0.087
Note: bold face representing signiﬁcant data.Sanchita et al. reported that the promoter hypermethylation of miR-
34c contributed to the downregulated protein expression in colon
cancer and that treatment with methyltransferase inhibitor resulted in
the re-expression of miR-34c, which was attributed to the growth inhi-
bition of both chemo-resistant and chemo-sensitive colon cancer cells.
This ﬁnding suggested that the downregulation of this microRNA-34c
may partly contribute to unregulated cellular growth and drug resis-
tance in colon cancer (Roy et al., 2012). Another study has shown that
the frequency of miR-34b/c methylation was signiﬁcantly higher in
small-cell lung cancer (SCLC) than in non-small-cell lung cancer
(NSCLC), miR-34b/c methylation promoted SCLC cell growth, invasion,
and migration. Thus, the aberrant methylation of miR-34b/c is impor-
tant in the pathogenesis of SCLC, which implies that miR-34b/c may
be a useful therapeutic target for SCLC (Tanaka et al., 2012). Similarly,
miR-34b/c expression was inversely correlated with miR-34b/c
methylation in chronic lymphocytic leukemia. MiR-34b re-expression
by demethylation treatment resulted in the repression of cellular prolif-
eration and increased cell death in MEC1 cells (Wang et al., 2014).
Moreover, a recent study identiﬁed that the abnormal methylation of
miR-34b/c was associated with a high probability of recurrence as
well as poor overall survival and disease-free survival. The promoter
hypermethylation of miR-34b/c was an independent prognostic factor
of stage I NSCLC (Wang et al., 2011).
Compared with the relevant ﬁndings on cancer, the understanding
of miR-34b/c methylation alterations in STSs remains very limited. In
this work, we measured the quantitative DNA methylation patterns of
miRNA34b/c CpG islands in STS tissues byusingMALDI-TOF-MS. Hierar-
chical clustering suggested that the quantitativemethylation patterns in
sarcoma tissue exhibited substantive differences from those in the
normal control group and the corresponding CpG units tend to cluster
together in STS tissues and showed higher methylation patterns. The
miR-34b/c gene was frequently methylated in STSs and the methylation
level of miR-34b/c was signiﬁcantly higher in STSs than in normal con-
trols. This work is the ﬁrst to evaluate the methylation level of individual
CpG islands of miR-34b/c within STSs. We found that methylation level
differed among individual CpG units, with the highest and lowest values
being 23% and10% in STS.Moreover, themethylation frequencies of three
CpG islands of miR-34b/c (CpG_1.2.3, CpG_4.5.6.7 and CpG_11.12.13)
were signiﬁcantly higher in the STS group than in the normal control
group (p b 0.001). Aberrant methylation was higher in SRTSs and
NRTSs than in normal controls, the difference was statistically signiﬁcant
(p b 0.05). These results indicated that the hypermethylation ofmiR-34b/
c might be an important mechanism in STS pathogenesis. However, the
methylation changes observed in SRTSs and NRTSs did not exhibit signif-
icant differences. In addition, we also observed that themethylation level
of each CpG island was not signiﬁcantly different between SRTSs and
NRTS. The result suggested no associationmay exist between themethyl-
ation patterns of miR-34b/c and the characteristics of STS genetics.
Our results are similar to previous ﬁndings (Vogt et al., 2011).
Although the participants in both studies had different genetic and
environmental backgrounds, Vogt et al. found a higher methylation
level of miR-34b/c in STSs by using methylation-speciﬁc PCR methods
Table 4
Association between miR-34b/c methylation and clinicopathologic features in STS patients.
CpG unit CpG site Clinical characteristics
Gender (Z/P)a Age (Z/P)a Tumor location
(χ2/P)b
Grade (χ2/P)b Tumor size (Z/P)a TNM stage (Z/P)a
Unit 1 CpG_1.2.3 −1.638 0.101 −0.092 0.927 2.186 0.702 4.425 0.109 −2.218 0.027⁎ −3.052 0.002⁎⁎
Unit 2 CpG_4.5.6.7 −1.430 0.153 −0.991 0.322 2.723 0.605 0.455 0.797 −0.605 0.545 −3.275 0.001⁎⁎
Unit 3 CpG_8 −1.453 0.146 −0.532 0.595 5.673 0.225 1.160 0.560 −0.265 0.791 −1.826 0.068
Unit 4 CpG_9.10 −0.425 0.671 −0.562 0.574 2.765 0.598 6.475 0.039⁎ −0.402 0.687 −4.098 0.000⁎⁎
Unit 5 CpG_11.12.13 −0.820 0.412 −1.284 0.199 5.728 0.220 0.157 0.925 −1.223 0.221 −2.779 0.005⁎⁎
Unit 6 CpG_14 −1.982 0.047⁎ −2.121 0.034⁎ 0.827 0.935 2.296 0.317 −1.241 0.215 −2.325 0.020⁎
Unit 7 CpG_15.16 −1.097 0.237 −0.743 0.457 3.361 0.339 0.213 0.899 −0.065 0.948 −0.865 0.387
Note: Bold face representing signiﬁcant data.
a Mann–Whitney U test (two-sided).
b Kruskal–Wallis H test (two-sided).
⁎ p b 0.05.
⁎⁎ p b 0.01.
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miR-34b/c methylation occurs in 45.45% (5/11) of the STS formalin-
ﬁxed parafﬁn-embedded (FFPE) samples in cultured STS cells (40%,16/
40) and in 75% (6/8) STS frozen tissue samples (Vogt et al., 2011). In
brief, with the application of the non-quantitative MSP approach to a
German population and the quantitative MassARRAY method to a Chi-
nese population, the consistency of the methylation of miR-34b/c CpG
islands in both studies strengthens the association between miR-34b/c
methylation and STSs. MiR-34b/c is reportedly subject to frequent inac-
tivation by CpG methylation in various human malignant tumors
(Beresneva et al., 2013; Nadal et al., 2013; Ng et al., 2014; Vogt et al.,
2011; Wu et al., 2014). However, our study is the ﬁrst to demonstrate
the aberrance methylation level of miR-34b/c in Chinese patients with
STSs.
DNAmethylation, which is an enzymatically catalyzed modiﬁcation
of DNA during cellular differentiation and embryogenesis, is related to
the modulation of genome function in response to life experiences
and behavior and affects gene function and the phenotype. Themodula-
tions may serve as a mechanism for life-long genome adaptation and
ethnic variations in DNAmethylation levels involved in life experiences,
such as lifestyle and dietary differences (Szyf, 2013; Szyf and Bick,
2013). Methylation is an important epigenetic modiﬁcation involved
in biological processes such as gene expression regulation, DNA struc-
ture, and control of transposable elements in mammalian development
and human diseases, including cancer (Liu et al., 2013; Varriale, 2014).
Existing studies have shown various STS-susceptible genes, such as
BMP2 and ASS1 genes, with abnormal DNA methylation in STSs, and
the methylation changes may be associated with the progression and
prognosis of STSs (Huang et al., 2013; Wolf et al., 2014). Another
study suggested that p16 (INK4a) mRNA and protein expressionFig. 4.Association between the level of DNAmethylation ofmiRNA34b/c and TNM stage in
STS patients (Mann–Whitney U-test).downregulation due to hypermethylation of p16 (INK4a) promoter
were observed inmalignant progressionwithin STSs andwere associat-
ed with reduced patient survival (Knosel et al., 2014). In this study, we
found aberrantmiR-34b/cmethylation occurs in STSs, we further inves-
tigated the possible associations between aberrant methylation and
clinical characteristics. To our knowledge, this study is the ﬁrst to
show that the DNA hypermethylation of miR-34b/c correlates with
late clinical stage in patients with STSs. We conclude that patients
with DNA hypermethylation of miR-34b/c had a high probability of
poor prognosis. However, we failed to acquire available survival data.
Our data show the signiﬁcant association between overall methylation
level of miRNA34b/c and gender, especially the CpG_14 methylation
status was signiﬁcantly higher in males than in females. However,
there were 61.4% of male and 38.6% of female in our sample, male
patients were more than female patients. Our data may require further
experimental veriﬁcation in order to ensure the accuracy of conclusion.
The previous data shown that gender-speciﬁc DNAmethylation existed
in mice and humans (Penaloza et al., 2014; Piferrer, 2013). The hyper-
methylation of RARB, KCNH5 and KCNH8 was found to be more
frequent in females than inmales in NSCLC (Hawes et al., 2010). Anoth-
er study showed that promoter methylation of miR-137 was associated
with female gender in oral rinse samples (Langevin et al., 2010). In our
study, the study group is mix of various sarcoma subtypes, we acknowl-
edged each with a very different inherent biological phenotype and
behavior. For example, a dermatoﬁbrosarcoma protuberan has very
little metastatic potential vs. synovial sarcoma. We are curious to
know whether hypermethylation of miR-34b/c was associated with
STS different subtypes or STSs with more aggressive behavior. But it is
regretful that there was no signiﬁcant association between overall
methylation level of miRNA34b/c and tumor subtypes. It may indicate
that methylation of miR-34b/c has nothing to do with the subtype of
STSs, and may also the samples are likely too small that they have no
trend. Age is an important factor for tumorigenesis. Our data show
that the CpG_14methylation levels of miR-34b/c weremarkedly higher
in senile patients. In addition, we found that CpG_1.2.3 methylation
levels were positively correlated with tumor size. In our study, we
found that CpG_9.10 methylation status had a positive correlation
with pathological grade, indicating that DNA hypermethylation of
miR-34b/c within CpG_9.10might be an important prognostic parame-
ter. These ﬁndings support the idea that the hypermethylation of miR-
34b/c might be correlated with the progression and prognostic of
STSs. However, our sample numbers are likely too small, further studies
with larger samples have to be conducted to conﬁrm our observation.
DNAmethylation is an importantmethod of epigenetic modiﬁcative
regulation, which subsequently results in transcriptional inhibition and
expression silencing of target gene. This process is an important ele-
ment in the regulation of various factors implicated in tumor develop-
ment. Strong evidence demonstrates a positive correlation between
the appearance of target gene methylation and the reduction in the
453Y. Xie et al. / Experimental and Molecular Pathology 98 (2015) 446–454level of target protein expression (Bauer et al., 2010; Rodriguez-Paredes
and Esteller, 2011). Previous studies have shown that hypermethylation
of miR-34b/c contributed to the down-regulation protein expression in
lung adenocarcinoma, colon cancer and chronic lymphocytic leukemia
(Nadal et al., 2013; Roy et al., 2012; Wang et al., 2014). In the present
study, aberrant miR-34b/c methylation occurs in STSs, it has been
hypothesized that miR-34b/c hypermethylation was related to the
down-regulation of miR-34b/c gene expression. Further studies are
needed to conﬁrm whether the aberrant methylation of miR-34b/c
inﬂuenced the expression level of miR-34b/c in STSs.
The alterations of tumor suppressor p53 pathway are highly
connected with various types of human cancers, plays a signiﬁcant
role in preventing tumor development and progression mostly through
its downstream target genes (Liao et al., 2014). The promoter regions of
miR-34b/c include a palindromic sequence that matches the canonical
p53-binding site, miR-34b/c expression may be induced by P53 in
response to DNA damage or cell stress (Wei et al., 2006). MiR-34b/c is
a direct target of p53, our study revealed a novel mechanism for miR-
34b/c regulation in STSs. According to previous data, expression of
miR-34b/c was signiﬁcantly down-regulated inmethylated lung adeno-
carcinoma primary tumors and cell lines, especially in those harboring a
P53 mutation (Nadal et al., 2013). Recently, the date showed that p53
mutations occur in STSs, p53 mutations were detected in 40.0% of
NRTSs and 13.0% SRTS. The frequency of p53mutations was signiﬁcantly
higher in cases with NRTSs than in cases with SRTS (Yin et al., 2012).
Although no statistical differences were observed inmiR-34b/c methyl-
ation level between SRTSs and NRTSs in our study, we found thatmeth-
ylation level was higher in NRTSs than in SRTSs. Thus, it was considered
whether there are any relationship between p53 mutations and miR-
34b/c hypermethylation in STSs. Clearly, further studies are required
to obtain a more complete understanding of association between P53
mutational status and miR-34b/c methylation in STSs. In addition, no
study has conﬁrmed whether dysregulated miR-34b/c can affect STS
progression. Therefore, the biological function of the miR-34b/c hyper-
methylation in STSs should be further analyzed to clarify this point by
mechanistic experiments.
5. Conclusion
This study illustrates that the hypermethylation of miR-34b/c CpG
islands is a relatively common event in STSs and is signiﬁcantly correlat-
ed with late clinical stage in patients with STSs. These ﬁndings indicate
that the hypermethylation of themiR-34b/cmay be pivotal to the onco-
genesis and development of STSs and may be a potential prognostic
factor for STSs.
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